Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
LG Chem will receive totaling up to $95.5 million for the China rights
The designation recognizes Seeq's expertise in enabling faster insights and better business outcomes for life sciences customers, including Bristol Myers Squibb, with advanced analytics innovations.
This partnership stemmed from a successful customer-supplier relationship spanning several years.
Sanjeev is currently the Country President for AstraZeneca Malaysia
He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels
Implants from the U.S. startup Allay Therapeutics are designed to relieve pain after knee surgery for up to three weeks
EC grants conditional marketing authorization based on the EFFISAYIL trial
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
